AGR Summary
Acorda Therapeutics Inc.
(NASD:ACOR)
Average
(65)
| Industry: | Biotechnology | Period End: | Mar 31, 2010 (Fiscal 2010 Q-1) | Statement Filing: | May 10, 2010 (10-Q) |
|---|---|---|---|---|---|
| Market Cap: | USD 1,229.3mm (Mid Cap) | Last Audit: | KPMG LLP | Rating Published: | Jun 18, 2010 |
OVERVIEW
Acorda Therapeutics Inc.
is currently rated as having
Average Accounting & Governance Risk (AGR).
This places them in the 65th
percentile among all companies, indicating higher accounting and governance risk than
35% of companies.
RISK SUMMARY
The forensic risk summary highlights material risks, if any, and lists the most material red flagged metric for each risk. AGR Impact shows the relative weight of the various red flagged metrics by risk type.
| Risk | AGR Impact | Top Flagged Metric |
|---|---|---|
| Corporate Governance Events | 0.0% | |
| High Risk Events | 0.0% | |
| Revenue Recognition | 36.2% | Inventory/Cost of Goods Sold |
| Expense Recognition | 39.6% | R&D Expense/Operating Expense |
| Asset-Liability Valuation | 24.2% | Intangible Assets/Assets |